Compare

Merck & Co./$MRK

1D1W1M3M6MYTD1Y5YMAX

About Merck & Co.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Ticker
$MRK
Sector
Health
Primary listing
NYSE
Employees
74,000

Merck & Co. Metrics

BasicAdvanced
$356B
146.10
$0.99
0.12
$3.40
2.35%

What the Analysts think about Merck & Co.

Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Analyst projections of the future price of Merck & Co. stock.

Bulls say / Bears say

Merck’s third-quarter sales and adjusted earnings beat expectations, and it raised the lower end of its 2026 sales forecast. This points to continued near-term operating strength. (Reuters)
Newer products are gaining scale: Winrevair sales rose 93% to $694 million, while the under-the-skin Keytruda QLEX generated $830 million in the quarter. Their growth could help broaden Merck’s revenue base. (Merck)
The pipeline has produced encouraging late-stage cancer data: intismeran plus Keytruda cut the risk of melanoma recurrence or death by 42%, and sac-TMT showed a survival benefit in endometrial cancer. These programmes could add future growth opportunities, although further development and approvals remain necessary. (Merck, Merck)
Merck remains heavily reliant on Keytruda, whose key patent protections are due to start expiring in 2028. Reuters also reports that Keytruda’s growth is expected to moderate as it approaches peak sales in some uses. (Reuters)
Some of the latest sales strength may reflect timing rather than lasting demand: Merck said about $550 million of third-quarter growth came from purchases made earlier than expected. Gardasil’s rebound also benefited from early US government buying, while demand in China has remained weak. (Reuters)
Merck and Daiichi Sankyo withdrew their US filing for cancer drug I-DXd after the FDA said the submitted data were not enough to support accelerated approval. That delays a potential launch and return on a major development partnership. (Fierce Biotech)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.

Merck & Co. Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Merck & Co. Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.